相似文献
1
Customized targeted therapy in Hodgkin lymphoma: hype or hope?
Hematol Oncol Clin North Am. 2014 Feb;28(1):105-22. doi: 10.1016/j.hoc.2013.10.004.
2
Targeting CD30 Using Brentuximab Vedotin in the Treatment of Hodgkin Lymphoma.
Cancer J. 2016 Jan-Feb;22(1):23-6. doi: 10.1097/PPO.0000000000000168.
3
The epidemiology and targeted therapies for relapsed and refractory CD30+ lymphomas.
Curr Med Res Opin. 2015 Mar;31(3):537-45. doi: 10.1185/03007995.2015.1008131. Epub 2015 Feb 9.
4
Anti-CD30 Antibodies for Hodgkin lymphoma.
Curr Hematol Malig Rep. 2010 Jul;5(3):140-7. doi: 10.1007/s11899-010-0053-y.
5
Targeted therapy in relapsed classical hodgkin lymphoma.
J Natl Compr Canc Netw. 2013 Aug;11(8):968-76. doi: 10.6004/jnccn.2013.0117.
6
The evolving role of targeted drugs in the treatment of Hodgkin lymphoma.
Expert Rev Hematol. 2017 Sep;10(9):775-782. doi: 10.1080/17474086.2017.1350167. Epub 2017 Jul 10.
7
Relapsed classic Hodgkin lymphoma with decreased CD30 expression after brentuximab and anti-CD30 CAR-T therapies.
Blood. 2022 Feb 10;139(6):951. doi: 10.1182/blood.2021013881.
8
CD30 and CD30-Targeted Therapies in Hodgkin Lymphoma and Other B cell Lymphomas.
Curr Hematol Malig Rep. 2016 Dec;11(6):480-491. doi: 10.1007/s11899-016-0345-y.
9
Novel Therapies in the Treatment of Hodgkin Lymphoma.
Curr Treat Options Oncol. 2021 Mar 23;22(5):42. doi: 10.1007/s11864-021-00840-5.
10
Challenges and perspectives in the immunotherapy of Hodgkin lymphoma.
Eur J Cancer. 2017 Nov;85:67-77. doi: 10.1016/j.ejca.2017.08.014. Epub 2017 Sep 9.
引用本文的文献
1
Pediatric Hodgkin lymphoma: biomarkers, drugs, and clinical trials for translational science and medicine.
Oncotarget. 2016 Oct 11;7(41):67551-67573. doi: 10.18632/oncotarget.11509.
2
HLA-G expression and role in advanced-stage classical Hodgkin lymphoma.
Eur J Histochem. 2016 Apr 11;60(2):2606. doi: 10.4081/ejh.2016.2606.
3
Simultaneous occurrence of Hodgkin's lymphoma and multiple myeloma: A case report and review of the literature.
Oncol Lett. 2016 Jun;11(6):4139-4143. doi: 10.3892/ol.2016.4503. Epub 2016 Apr 27.
4
The favorable role of homozygosity for killer immunoglobulin-like receptor (KIR) A haplotype in patients with advanced-stage classic Hodgkin lymphoma.
J Hematol Oncol. 2016 Mar 16;9:26. doi: 10.1186/s13045-016-0255-4.
本文引用的文献
1
Early thymus and activation-regulated chemokine (TARC) reduction and response following panobinostat treatment in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplant.
Leuk Lymphoma. 2014 May;55(5):1053-60. doi: 10.3109/10428194.2013.820287. Epub 2013 Aug 5.
2
Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant.
Leuk Lymphoma. 2013 Nov;54(11):2531-3. doi: 10.3109/10428194.2013.798868. Epub 2013 Jun 5.
3
Risk of therapy-related secondary leukemia in Hodgkin lymphoma: the Stanford University experience over three generations of clinical trials.
J Clin Oncol. 2013 Feb 10;31(5):592-8. doi: 10.1200/JCO.2012.44.5791. Epub 2013 Jan 7.
4
Brentuximab vedotin combined with donor lymphocyte infusions for early relapse of Hodgkin lymphoma after allogeneic stem-cell transplantation induces tumor-specific immunity and sustained clinical remission.
J Clin Oncol. 2013 Feb 10;31(5):e59-63. doi: 10.1200/JCO.2012.43.6832. Epub 2012 Dec 26.
5
Baseline serum TARC levels predict therapy outcome in patients with Hodgkin lymphoma.
Am J Hematol. 2013 Feb;88(2):113-5. doi: 10.1002/ajh.23361. Epub 2012 Dec 8.
6
The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and Leukemia Group B 50602 (Alliance).
Leuk Lymphoma. 2013 Jul;54(7):1405-10. doi: 10.3109/10428194.2012.744453. Epub 2013 Jan 4.
7
Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496).
J Clin Oncol. 2013 Feb 20;31(6):684-91. doi: 10.1200/JCO.2012.43.4803. Epub 2012 Nov 26.
8
The emerging role of PET in Hodgkin lymphoma patients receiving autologous stem cell transplant.
Expert Rev Hematol. 2012 Oct;5(5):483-6. doi: 10.1586/ehm.12.41.
9
Autophagy controls everolimus (RAD001) activity in mantle cell lymphoma.
Autophagy. 2013 Jan;9(1):115-7. doi: 10.4161/auto.22483. Epub 2012 Oct 18.
10
Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK center.
Haematologica. 2013 Apr;98(4):611-4. doi: 10.3324/haematol.2012.069393. Epub 2012 Oct 12.
Zotero 插件